,44 Following data from Yao and colleagues13 linking the NLRP3 inflammasome to AF, and multiple cardiovascular outcome trials demonstrating a benefit with anti-inflammatory therapies for the secondary prevention of ASCVD, further investigation is required to determine a role for anti-inflammatory therapies for prevention and treatment of AF. Here, NLRP3 is linked to atherosclerosis.